Dichlorphenamide

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Daranide; Keveyis (Taro)
  • INDICATIONS: Glaucoma (Daranide), primary hyperkalemic or hypokalemic periodic paralysis (Keveyis)
  • CLASS: Carbonic anhydrase inhibitor
  • HALF-LIFE: 8 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aspirin, Cyclosporine, Diflunisal, Lithium, Metformin, Primidone, Salicylates, Salsalate

PREGNANCY CATEGORY: C

Our database has 22 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
OTHER.


Page last updated 07/31/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top